Upstream Bio, Inc. (UPB) - Total Assets
Based on the latest financial reports, Upstream Bio, Inc. (UPB) holds total assets worth $391.19 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore debt repayment capacity of Upstream Bio, Inc. to assess how comfortably operating cash covers total debt obligations.
Upstream Bio, Inc. - Total Assets Trend (2022–2024)
This chart illustrates how Upstream Bio, Inc.'s total assets have evolved over time, based on quarterly financial data. See UPB total equity for net asset value and shareholders' equity analysis.
Upstream Bio, Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Upstream Bio, Inc.'s total assets of $391.19 Million consist of 99.5% current assets and 0.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 67.7% |
| Accounts Receivable | $1.18 Million | 0.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2022–2024)
This chart illustrates how Upstream Bio, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Upstream Bio, Inc. (UPB) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Upstream Bio, Inc.'s current assets represent 99.5% of total assets in 2024, an increase from 99.1% in 2022.
- Cash Position: Cash and equivalents constituted 67.7% of total assets in 2024, down from 92.3% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is accounts receivable at 0.2% of total assets.
Upstream Bio, Inc. Competitors by Total Assets
Key competitors of Upstream Bio, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Sk Biopharmaceuticals Co Ltd
KO:326030
|
Korea | ₩1.20 Trillion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $398.69 Million |
|
TELIX Pharmaceuticals Ltd
AU:TLX
|
Australia | AU$1.19 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Theravance Biopharma Inc
F:0TB
|
Germany | €415.46 Million |
Upstream Bio, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 32.67 | 20.90 | 17.96 |
| Quick Ratio | 32.67 | 20.90 | 17.96 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $377.11 Million | $216.40 Million | $110.48 Million |
Upstream Bio, Inc. - Advanced Valuation Insights
This section examines the relationship between Upstream Bio, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.25 |
| Latest Market Cap to Assets Ratio | 0.76 |
| Asset Growth Rate (YoY) | 311.0% |
| Total Assets | $481.72 Million |
| Market Capitalization | $366.92 Million USD |
Valuation Analysis
Below Book Valuation: The market values Upstream Bio, Inc.'s assets below their book value (0.76x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Upstream Bio, Inc.'s assets grew by 311.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Upstream Bio, Inc. (2022–2024)
The table below shows the annual total assets of Upstream Bio, Inc. from 2022 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $481.72 Million | +311.03% |
| 2023-12-31 | $117.20 Million | +534.26% |
| 2022-12-31 | $18.48 Million | -- |
About Upstream Bio, Inc.
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 clinical development for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps, and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporat… Read more